Company intelligence / Profile preview

Ascelia Pharma

Ownership: Private
Development stage: Other

Overview

CMC Contrast developed "CMC 001", an orally administered manganese-based MRI contrast agent for abdominal MR imaging. Phase I and IIa clinical trials showed excellent contrast-enhancing properties with minimal adverse effects. The product entered Phase III clinical development. It was granted orphan drug designation for use as a targeted diagnostic MRI agent in certain indications.

Therapeutic areas: GastroenterologyOncology
Modalities: Small moleculeMRI contrast agent
Industry: Medical Imaging

Beyond the preview

Go deeper on Ascelia Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ascelia Pharma.

Explore the full profile